Back to Search
Start Over
PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia.
- Source :
-
Journal of internal medicine [J Intern Med] 2021 May; Vol. 289 (5), pp. 749-751. Date of Electronic Publication: 2020 Dec 19. - Publication Year :
- 2021
- Subjects :
- Antiviral Agents pharmacology
Cholesterol, LDL blood
Endothelium, Vascular metabolism
Endothelium, Vascular physiopathology
Humans
Lipoprotein(a) blood
PCSK9 Inhibitors
Research Design
SARS-CoV-2 drug effects
Anticholesteremic Agents pharmacology
COVID-19 blood
COVID-19 immunology
Hyperlipoproteinemia Type II blood
Hyperlipoproteinemia Type II drug therapy
Interferons immunology
Proprotein Convertase 9 blood
COVID-19 Drug Treatment
Subjects
Details
- Language :
- English
- ISSN :
- 1365-2796
- Volume :
- 289
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Journal of internal medicine
- Publication Type :
- Editorial & Opinion
- Accession number :
- 33222314
- Full Text :
- https://doi.org/10.1111/joim.13210